Last update Aug. 7, 2026
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Linaclotide in other languages or writings:
| Variable | Value | Unit |
|---|---|---|
| Oral Bioavail. | 0 | % |
| Molecular weight | 1.527 | daltons |
| Theoretical Dose | 0.00004 | mg/Kg/d |
| Relative Dose | 0.8 | % |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A synthetic peptide consisting of 14 amino acids, related to the family of endogenous guanylate peptides. Indicated for moderate to severe constipation associated with irritable bowel syndrome and for chronic idiopathic constipation.
It acts locally in the intestine without being absorbed (EMA 2016). It is metabolised in the intestine to produce its main active metabolite, destyrosin. Both linaclotide and destyrosin are broken down by intestinal enzymes and converted into natural amino acids.
In a multicentre study measuring levels in breast milk, quantities below the limit of quantification were detected (Crittenden 2021).
Its pharmacokinetic data (zero or negligible intestinal absorption with undetectable plasma levels and a high molecular weight) make it highly unlikely that significant quantities will pass into breast milk (EMA 2016).